Westfield Capital Management Co. LP Acquires 544 Shares of Eli Lilly and Company $LLY

Westfield Capital Management Co. LP raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,549 shares of the company’s stock after purchasing an additional 544 shares during the period. Eli Lilly and Company accounts for about 1.2% of Westfield Capital Management Co. LP’s holdings, making the stock its 14th largest holding. Westfield Capital Management Co. LP’s holdings in Eli Lilly and Company were worth $298,277,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp raised its position in Eli Lilly and Company by 0.6% during the 3rd quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after purchasing an additional 219,590 shares during the last quarter. Capital Research Global Investors raised its position in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Wellington Management Group LLP raised its position in Eli Lilly and Company by 4.1% during the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after purchasing an additional 574,229 shares during the last quarter. Finally, Norges Bank bought a new position in Eli Lilly and Company during the 4th quarter valued at approximately $12,976,634,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Health’s latest move is being seen as another win for Eli Lilly’s LillyDirect ecosystem, strengthening its position in the chronic weight-management market and potentially expanding access to patients using Lilly’s obesity treatments. Article Title
• Positive Sentiment: WW International said its WeightWatchers Med+ program is now available through LillyDirect, which could help broaden the reach of GLP-1-based weight-loss care and reinforce demand around Eli Lilly’s obesity franchise. Article Title
• Positive Sentiment: Eli Lilly’s $1.9 billion partnership with Ascidian Therapeutics adds another growth avenue outside obesity, signaling continued investment in genetic medicine and kidney-disease therapies that could diversify future revenue. Article Title
• Positive Sentiment: Multiple commentary pieces highlighted Lilly as a buy and noted continued strength in its obesity, gene-editing, vaccine, and cancer pipelines, which may be supporting investor sentiment. Article Title
• Neutral Sentiment: Several market-watchlist and “stock of the day” articles kept Eli Lilly in the spotlight, but they did not add material new fundamentals beyond broader bullish coverage. Article Title
• Negative Sentiment: The Ascidian deal was also reported alongside a stock dip in one headline, suggesting some investors may be cautious about the size of Lilly’s acquisition and partnership spending even as they like the strategic logic. Article Title

Analyst Ratings Changes

A number of research firms have commented on LLY. Bank of America upped their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Finally, Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Stock Up 4.3%

Shares of NYSE:LLY opened at $1,125.00 on Friday. The stock has a fifty day simple moving average of $970.24 and a two-hundred day simple moving average of $1,012.19. The stock has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 39.96, a PEG ratio of 1.18 and a beta of 0.53. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,149.10. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.